Pernix Therapeutics (PTX) Misses Q1 EPS by 36c, Withdraws Guidance

Pernix Therapeutics (NASDAQ: PTX) reported Q1 EPS of ($0.42), $0.36 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $32.5 million versus the consensus estimate of $44.55 million.

• Pernix is temporarily withdrawing its prior 2016 financial guidance.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance
• Employers Holdings (EIG) Misses Q1 EPS by 2c